Clinical Trial: Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms

Brief Summary: This study will help to determine whether the medication, topiramate, reduces alcohol use among adolescents with alcohol dependence. It will also help answer the question, "How does topiramate reduce drinking in teenagers?" Understanding how topiramate may reduce drinking in adolescents would allow for a more targeted pharmacotherapeutic approach to treatment and help to identify additional medications that may hold promise for improving treatment outcomes for youth.

Detailed Summary: Adolescent alcohol use is associated with myriad adverse legal, health, and educational consequences and contributes to the leading causes of mortality among youth. Yet despite the magnitude of this public health problem, treatment initiatives for youth remain inadequate. Given these data, the National Institute on Alcohol Abuse and Alcoholism identified the critical need for medications development research for youth with the goal of identifying promising agents for which large-scale clinical trials are justified. The long-term goal of this research program is to improve pharmacotherapy for alcoholism. The major objective of this project is to address the urgent need for empirical data on medications that may benefit youth. For the past 10 years our research program has successfully paired human laboratory paradigms with ecological momentary assessment (EMA), whereby research participants use handheld electronic diaries to monitor their drinking, craving, and sensitivity to alcohol in real time in their natural environment. Using this approach, we identified mechanisms by which medications act and patient characteristics that moderate these effects. The proposed study will test if and how topiramate (TPM), an anticonvulsant shown to be efficacious for treating adults, reduces drinking in youth. To this end, we will randomize adolescent problem drinkers to TPM or placebo for 8 weeks, in combination with biweekly motivational enhancement therapy sessions, using a two-group, double-blind design. While at the target dose (200 mg/day) youth will complete EMA in their natural environment. In addition, youth will complete alcohol cue reactivity assessments in the laboratory to test the effects of TPM on cue-elicited craving and physiological reactivity in a controlled environment. Youth will complete 6- and 12-month follow-up assessments to determine whether any benefits are sustained. This study will provide much needed data on the tolerability and efficacy of TPM with a
Sponsor: Brown University

Current Primary Outcome: Alcohol use [ Time Frame: 9-week medication phase ]

Days of abstinence from drinking and of clinically significant drinking


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Alcohol craving [ Time Frame: Weekly for 9 weeks, 6- and 12-month follow-up assessments ]
    Probability and intensity of subjective craving
  • Cognitive functioning [ Time Frame: Baseline, week 5, and 6-month follow-up assessment ]
    Neuropsychological test battery


Original Secondary Outcome: Same as current

Information By: Brown University

Dates:
Date Received: July 11, 2012
Date Started: July 2012
Date Completion: August 2016
Last Updated: January 11, 2016
Last Verified: January 2016